Vinod Khatri, MD
Internal Medicine · Toledo, OHNPI 1093049678
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (52.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 90.4% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $5,569 and has fallen 89.4% since, to $588 in 2025. Among internal medicine clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 39 payments — averaging $170.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- Amgen$168
- GSK$86
- Boehringer Ingelheim$61
- Olympus America Inc.$59
- Inogen, Inc.$57
- plus $209 from 8 others
Across 14 payments — averaging $9710.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$92K
- United Therapeutics Corporation$44K
What the payments were for
- Travel & lodging$2,36836%
- Food & beverage$78612%
- Education$3,50053%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 13 | $6,014 |
| Amgen | 2 | $168 |
| GSK | 5 | $86 |
| Boehringer Ingelheim | 3 | $61 |
| Olympus America Inc. | 1 | $59 |
| Inogen, Inc. | 4 | $57 |
| AstraZeneca | 3 | $46 |
| Sanofi | 2 | $30 |
| Bristol Myers Squibb | 1 | $29 |
| Merck | 1 | $23 |
| United Therapeutics Corporation | 1 | $22 |
| Mylan Specialty L.p. | 1 | $22 |
| Electromed, Inc. | 1 | $19 |
| Pfizer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,953
How this compares
$6,654 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 29 | $367,754 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 145 | $139,852 |
| Spiriva RespimatTiotropium Bromide | 105 | $72,060 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 98 | $51,687 |
| Incruse ElliptaUmeclidinium Bromide | 108 | $42,599 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 49 | $31,548 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $22,991 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 63 | $22,414 |
| Advair HfaFluticasone Propion/Salmeterol | 54 | $20,733 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $16,179 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $13,835 |
| Spiriva HandihalerTiotropium Bromide | 15 | $13,592 |
| DuleraMometasone/Formoterol | 30 | $10,546 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 298 | $9,949 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 59 | $6,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $61 | $455,993151 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $86 | $257,130385 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $46 | $45,38392 claims |
| MerckDulera | $23 | $10,54630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Toledo
- Yacin ZawamToledo$43K
- Hassan MalikAkron$1.7M
- Cyrus HarrisCleveland$726K
- Nina DeepWesterville$614K
- Necklall KhooblallAustintown$448K
- Daniel WeissMentor$406K
- Richard KimDayton$326K
- Marina MagreyCleveland$312K
- Lisa LarkinCincinnati$276K
- Gregg FaimanMayfield Hts$274K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.